Results 41 to 50 of about 28,600 (213)

Olanzapine Overdose in a Pin Point Pupil with Altered Sensorium [PDF]

Asia Pacific Journal of Medical Toxicology, 2017
Background:Olanzapine is a highly tolerable and easily affordable atypical antipsychotic drug which has been commonly prescribed in both inpatient and outpatient settings for several mental disorders.
Naresh Midha, Arup Misra, Vivek Chhabra, Gopal Bohra   +3 more
doaj   +1 more source

An ETH‐LAD trip with unfavourable consequences: A case report

British Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler, Michaela Sommer, Annette Zschiesche, Anne Stürzebecher, Christina Grumann, Volker Auwärter, Maren Hermanns‐Clausen   +6 more
wiley   +1 more source

Effect of metformin on olanzapine-induced weight gain: A 12-week randomised open-label study

Journal of Clinical Sciences
Background: Olanzapine is an atypical antipsychotic used in schizophrenia and bipolar affective disorder, but it is associated with weight gain and metabolic syndrome.
G. Chetan Kumar, N. Sarala, M. Mohan Reddy, H. Manjunath   +3 more
doaj   +1 more source

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth

Clinical Pharmacology &Therapeutics, EarlyView.
Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples, Shayna R. Killam, Karen E. Brown, Rachel Dalton, Elizabeth Sather, Qiang Chen, Joshua Loveland, Corbin Schwanke, Abdallah F. Elias, Kristin L. Bigos, Erica L. Woodahl   +10 more
wiley   +1 more source

Peripheral edema due to olanzapine use: a case report

Psychiatry and Behavioral Sciences, 2016
Peripheral edema is associated with multiple medical etiologies (systemic disorders, hypoproteinemia, long-term immobility, cancer diseases) and drugs (nonsteroidal anti-inflammatory drugs, antihypertensives, steroids, and immunsupressive agents ...
Musa Şahpolat, Umit Sertan Copoğlu, Mehmet Hanifi Kokacya   +2 more
doaj   +1 more source

Hyperbaric oxygen exposure alleviate metabolic side-effects of olanzapine treatment and is associated with Langerhans islet proliferation in rats

Pathology and Oncology Research, 2022
Introduction: Olanzapine (OLZ) is one of the second-generation antipsychotics drugs (APDs) used to treat several psychiatric illnesses. Olanzapine treatment is often associated with many metabolic side effects in a dose dependent manner such as obesity ...
Mohammad AlQudah, Mohammad Khalifeh, Rasha Al-Azaizeh, Amr Masaadeh, Amr Masaadeh, Omar M. Al-Rusan, Omar M. Al-Rusan, Husam K. Haddad   +7 more
doaj   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Virtual Twin Approach Using Physiologically Based Pharmacokinetic Modeling to Support Precision Dosing of Valproic Acid in Geriatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang, Dong‐Gyu Heo, Eunjin Hong   +2 more
wiley   +1 more source

Antipsychotic Drug Interactions and Short‐Term Mortality Risk in People With Dementia: A National Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Antipsychotics are often prescribed in the management of behaviors and psychological symptoms of dementia. While the potential harms of antipsychotic use in people with dementia have been established, little is known about the risk associated with antipsychotic drug–drug interactions (DDIs). This study aims to examine the patterns of antipsychotic DDIs
Edward C.Y. Lau, Grace H. Shim, Chin Hang Yiu, Sarah N. Hilmer, Yun‐Hee Jeon, Weisi Chen, Christine Y. Lu, Edwin C.K. Tan   +7 more
wiley   +1 more source

Association between olanzapine concentration and metabolic dysfunction in drug-naive and chronic patients: similarities and differences

npj Schizophrenia, 2022
Second-generation antipsychotics are widely used to treat schizophrenia but their use could induce metabolic dysfunction. To balance efficacy and side effects, various guidelines recommend the use of therapeutic drug monitoring.
Dongyu Kang, Jinjun Lu, Wenqing Liu, Ping Shao, Renrong Wu   +4 more
doaj   +1 more source